Related references
Note: Only part of the references are listed.B cells and tertiary lymphoid structures promote immunotherapy response
Beth A. Helmink et al.
NATURE (2020)
Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial
Suzanne L. Topalian et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
The Society for Immunotherapy of Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation
Janis M. Taube et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Spatial Density and Distribution of Tumor-Associated Macrophages Predict Survival in Non-Small Cell Lung Carcinoma
Xiang Zheng et al.
CANCER RESEARCH (2020)
Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC
Roy S. Herbst et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
The 'AstroPath' platform for spatially resolved, single cell analysis of the tumor microenvironment (TME) using multispectral immunofluorescence (mIF)
Sneha Berry et al.
CANCER RESEARCH (2020)
Automated image analysis of NSCLC biopsies to predict response to anti-PD-L1 therapy
Sonja Althammer et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade: A Systematic Review and Meta-analysis
Steve Lu et al.
JAMA ONCOLOGY (2019)
Eight-Color Multiplex Immunohistochemistry for Simultaneous Detection of Multiple Immune Checkpoint Molecules within the Tumor Microenvironment
Mark A. J. Gorris et al.
JOURNAL OF IMMUNOLOGY (2018)
Implications of the tumor immune microenvironment for staging and therapeutics
Janis M. Taube et al.
MODERN PATHOLOGY (2018)
Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti-PD-1 Therapies in Metastatic Melanoma
Douglas B. Johnson et al.
CLINICAL CANCER RESEARCH (2018)
PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project
Ming Sound Tsao et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Quantitative assessment of tumor-infiltrating lymphocytes and immunotherapy outcome in metastatic melanoma
Pok Fai Wong et al.
CANCER RESEARCH (2018)
A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers
S. N. Gettinger et al.
NATURE COMMUNICATIONS (2018)
Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab
Nicolas A. Giraldo et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Validation of multiplex immunofluorescence panels using multispectral microscopy for immune-profiling of formalin-fixed and paraffin-embedded human tumor tissues
Edwin R. Parra et al.
SCIENTIFIC REPORTS (2017)
A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer
David L. Rimm et al.
JAMA ONCOLOGY (2017)
Multiparametric immune profiling in HPV-oral squamous cell cancer
Zipei Feng et al.
JCI INSIGHT (2017)
PD-L1 Testing in Cancer Challenges in Companion Diagnostic Development
Aaron R. Hansen et al.
JAMA ONCOLOGY (2016)
PD-1/PD-L1 inhibitors
Joel Sunshine et al.
CURRENT OPINION IN PHARMACOLOGY (2015)
Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
Janis M. Taube et al.
CLINICAL CANCER RESEARCH (2014)
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst et al.
NATURE (2014)
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh et al.
NATURE (2014)
Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
Janis M. Taube et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Share Paper
